Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · Real-Time Price · USD
2.870
+0.030 (1.06%)
Feb 21, 2025, 4:00 PM EST - Market closed
Synaptogenix Employees
Synaptogenix had 5 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,826,481
Market Cap
3.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5 | 0 | - |
| Dec 31, 2022 | 5 | 1 | 25.00% |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SNPX News
- 2 months ago - Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - PRNewsWire
- 5 months ago - Synaptogenix Announces $5.0 Million Financing - PRNewsWire
- 7 months ago - Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - PRNewsWire
- 8 months ago - Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - PRNewsWire
- 10 months ago - Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery - PRNewsWire
- 10 months ago - Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire
- 11 months ago - Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing - PRNewsWire
- 1 year ago - Synaptogenix President Daniel L. Alkon, M.D. - PRNewsWire